纳米卡介苗改善膀胱癌的免疫治疗效果

曾胜; 邢绍强; 张毅飞; 王海峰; 刘谦

doi:10.1631/jzus.B2300392

Your Location：

Home >

Browse articles >

纳米卡介苗改善膀胱癌的免疫治疗效果

Scan for full text

文章被引用时，请邮件提醒。

Submit

Review | Updated：2024-07-17

纳米卡介苗改善膀胱癌的免疫治疗效果
Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment
浙江大学学报（英文版）（B辑：生物医学和生物技术） 2024年25卷第7期页码：557-567
Affiliations：

1.Department of Urology, Tianjin First Central Hospital, Tianjin 300192, China
2.Department of Urology, First Central Clinical College, Tianjin Medical University, Tianjin 300192, China
Funds：

the Tianjin Natural Science Foundation(21JCYBJC00220;22JCQNJC01640);the Tianjin Health Science and Technology Project(ZC20162);the Tianjin Key Medical Discipline (Specialty) Construction Project, and the National Natural Science Foundation of China(82202323)
DOI：10.1631/jzus.B2300392
中图分类号：
CSTR：
纸质出版日期： 2024-07-15 ，

网络出版日期： 2024-07-11 ，

收稿日期： 2023-06-04 ，

修回日期： 2023-08-29 ，
Accepted：

曾胜,邢绍强,张毅飞等.纳米卡介苗改善膀胱癌的免疫治疗效果[J].浙江大学学报（英文版）（B辑：生物医学和生物技术）,2024,25(07):557-567.

Sheng ZENG, Shaoqiang XING, Yifei ZHANG, et al. Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2024,25(7):557-567.
曾胜,邢绍强,张毅飞等.纳米卡介苗改善膀胱癌的免疫治疗效果[J].浙江大学学报（英文版）（B辑：生物医学和生物技术）,2024,25(07):557-567. DOI： 10.1631/jzus.B2300392.

Sheng ZENG, Shaoqiang XING, Yifei ZHANG, et al. Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2024,25(7):557-567. DOI： 10.1631/jzus.B2300392.

摘要

癌症免疫治疗已成为继手术、放疗和化疗之后的第四大主流治疗选择，并取得了令人鼓舞的成果。肿瘤免疫治疗通过调动或激发机体自身的免疫功能，从而抑制和杀伤肿瘤细胞。然而，肿瘤免疫治疗作为一种新兴的治疗手段，由于缺乏有效的免疫细胞传递途径以及具有较高的毒副作用，在临床上的应用受到限制。近年来，纳米材料和基因工程在保护抗原递送、激活靶向T细胞、调节免疫抑制的肿瘤微环境和提高治疗效果等方面显示出巨大的潜力。卡介苗是一种用于预防结核病的减毒牛分枝杆菌活疫苗，于1927年首次报道其抗肿瘤活性。卡介苗可通过诱导多种细胞因子和趋化因子激活免疫系统，其特异性免疫和炎症反应可发挥抗肿瘤作用。20世纪70年代，卡介苗首次作为治疗膀胱癌的膀胱灌注药物，有效地提高了免疫抗肿瘤活性，防止肿瘤复发。最近，纳米卡介苗和基因工程卡介苗因其能诱导更强且更稳定的免疫反应，被提出作为膀胱癌的治疗方案。在本研究中，我们概述了纳米卡介苗和基因工程卡介苗用于膀胱癌免疫治疗的发展，并回顾了它们的潜力和挑战。

Abstract

Cancer immunotherapy has rapidly become the fourth mainstream treatment alternative after surgery

radiotherapy

and chemotherapy

with some promising results. It aims to kill tumor cells by mobilizing or stimulating cytotoxic immune cells. However

the clinical applications of tumor immunotherapies are limited owing to a lack of adequate delivery pathways and high toxicity. Recently

nanomaterials and genetic engineering have shown great potential in overcoming these limitations by protecting the delivery of antigens

activating targeted T cells

modulating the immunosuppressive tumor microenvironment

and improving the treatment efficacy. Bacillus Calmette-Guérin (BCG) is a live attenuated

Mycobacterium bovis

vaccine used to prevent tuberculosis

which was first reported to have antitumor activity in 1927. BCG therapy can activate the immune system by inducing various cytokines and chemokines

and its specific immune and inflammatory responses exert antitumor effects. BCG was first used during the 1970s as an intravesical treatment agent for bladder cancer

which effectively improved immune antitumor activity and prevented tumor recurrence. More recently

nano-BCG and genetically engineered BCG have been proposed as treatment alternatives for bladder cancer due to their ability to induce str

onger and more stable immune responses. In this study

we outline the development of nano-BCG and genetically engineered BCG for bladder cancer immunotherapy and review their potential and associated challenges.

关键词

膀胱癌卡介苗纳米载体基因工程免疫治疗

Keywords

Bladder cancerBacillus Calmette-Guérin vaccineNanocarrierGenetic engineeringImmunotherapy

references

Akazawa T, Masuda H, Saeki Y, et al., 2004. Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. Cancer Res, 64(2):757-764. https://doi.org/10.1158/0008-5472.can-03-1518https://doi.org/10.1158/0008-5472.can-03-1518

Álvarez-Maestro M, Guerrero-Ramos F, Rodríguez-Faba O, et al., 2021. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC). Actas Urol Esp, 45(2):93-102. https://doi.org/10.1016/j.acuro.2020.08.003https://doi.org/10.1016/j.acuro.2020.08.003

Andersen CS, Dietrich J, Agger EM, et al., 2007. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect Immun, 75(1):408-416. https://doi.org/10.1128/iai.01290-06https://doi.org/10.1128/iai.01290-06

Azuma I, Seya T, 2001. Development of immunoadjuvants for immunotherapy of cancer. Int Immunopharmacol, 1(7):1249-1259. https://doi.org/10.1016/s1567-5769(01)00055-8https://doi.org/10.1016/s1567-5769(01)00055-8

Babjuk M, Burger M, Capoun O, et al., 2022. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol, 81(1):75-94. https://doi.org/10.1016/j.eururo.2021.08.010https://doi.org/10.1016/j.eururo.2021.08.010

Bevers RFM, Kurth KH, Schamhart DHJ, 2004. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer, 91(4):607-612. https://doi.org/10.1038/sj.bjc.6602026https://doi.org/10.1038/sj.bjc.6602026

Bhindi B, Kool R, Kulkarni GS, et al., 2021. Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer – Abridged version. Can Urol Assoc J, 15(8):230-239. https://doi.org/10.5489/cuaj.7487https://doi.org/10.5489/cuaj.7487

Böhle A, Brandau S, 2003. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol, 170(3):964-969. https://doi.org/10.1097/01.ju.0000073852.24341.4ahttps://doi.org/10.1097/01.ju.0000073852.24341.4a

Brandau S, Suttmann H, 2007. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother, 61(6):299-305. https://doi.org/10.1016/j.biopha.2007.05.004https://doi.org/10.1016/j.biopha.2007.05.004

Burger M, Catto JWF, Dalbagni G, et al., 2013. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol, 63(2):234-241. https://doi.org/10.1016/j.eururo.2012.07.033https://doi.org/10.1016/j.eururo.2012.07.033

Buss JH, Begnini KR, Bender CB, et al., 2018. Nano-BCG: a promising delivery system for treatment of human bladder cancer. Front Pharmacol, 8:977. https://doi.org/10.3389/fphar.2017.00977https://doi.org/10.3389/fphar.2017.00977

Cho MJ, Kim MJ, Kim K, et al., 2019. The immunotherapeutic effects of recombinant Bacillus Calmette-Guérin resistant to antimicrobial peptides on bladder cancer cells. Biochem Biophys Res Commun, 509(1):167-174. https://doi.org/10.1016/j.bbrc.2018.12.097https://doi.org/10.1016/j.bbrc.2018.12.097

Choi SY, Kim SJ, Chi BH, et al., 2015. Modulating the internalization of bacille Calmette-Guérin by cathelicidin in bladder cancer cells. Urology, 85(4):964.e7-964.e12. https://doi.org/10.1016/j.urology.2014.12.028https://doi.org/10.1016/j.urology.2014.12.028

Chou R, Selph S, Buckley DI, et al., 2017. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol, 197(5):1189-1199. https://doi.org/10.1016/j.juro.2016.12.090https://doi.org/10.1016/j.juro.2016.12.090

Erdoğar N, Iskit AB, Eroğlu H, et al., 2015. Antitumor efficacy of bacillus Calmette-Guerin loaded cationic nanoparticles for intravesical immunotherapy of bladder tumor induced rat model. J Nanosci Nanotechnol, 15(12):‍‍10156-10164. https://doi.org/10.1166/jnn.2015.11690https://doi.org/10.1166/jnn.2015.11690

Fleischmann JD, Park MC, Hassan MO, 1993. Fibronectin expression on surgical specimens correlated with the response to intravesical bacillus Calmette-Guerin therapy. J Urol, 149(2):268-271. https://doi.org/10.1016/s0022-5347(17)36052-4https://doi.org/10.1016/s0022-5347(17)36052-4

Gadiot J, Hooijkaas AI, Kaiser ADM, et al., 2011. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer, 117(10):2192-2201. https://doi.org/10.1002/cncr.25747https://doi.org/10.1002/cncr.25747

Galon J, Bruni D, 2019. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov, 18(3):197-218. https://doi.org/10.1038/s41573-018-0007-yhttps://doi.org/10.1038/s41573-018-0007-y

Gong C, Qi T, Wei X, et al., 2013. Thermosensitive polymeric hydrogels as drug delivery systems. Curr Med Chem, 20(1):79-94. https://doi.org/10.2174/0929867311302010009https://doi.org/10.2174/0929867311302010009

Grode L, Seiler P, Baumann S, et al., 2005. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest, 115(9):2472-2479. https://doi.org/10.1172/jci24617https://doi.org/10.1172/jci24617

Grode L, Ganoza CA, Brohm C, et al., 2013. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine, 31(9):1340-1348. https://doi.org/10.1016/j.vaccine.2012.12.053https://doi.org/10.1016/j.vaccine.2012.12.053

Joraku A, Homhuan A, Kawai K, et al., 2009. Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin. BJU Int, 103(5):686-693. https://doi.org/10.1111/j.1464-410X.2008.08235.xhttps://doi.org/10.1111/j.1464-410X.2008.08235.x

Kawai K, Miyazaki J, Joraku A, et al., 2013. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci, 104(1):22-27. https://doi.org/10.1111/cas.12075https://doi.org/10.1111/cas.12075

Kim HS, Seo HK, 2021. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer. Investig Clin Urol, 62(4):361-377. https://doi.org/10.4111/icu.20200602https://doi.org/10.4111/icu.20200602

Kim JH, Choi J, Kim M, et al., 2022. Immunotherapeutic effects of recombinant Bacillus Calmette-Guérin containing sic gene in ex vivo and in vivo bladder cancer models. Investig Clin Urol, 63(2):228-237. https://doi.org/10.4111/icu.20210425https://doi.org/10.4111/icu.20210425

Kleinnijenhuis J, Quintin J, Preijers F, et al., 2014. Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J Innate Immun, 6(2):152-158. https://doi.org/10.1159/000355628https://doi.org/10.1159/000355628

Kovács M, Halfmann A, Fedtke I, et al., 2006. A functional dlt operon, encoding proteins required for incorporation of D-alanine in teichoic acids in gram-positive bacteria, confers resistance to cationic antimicrobial peptides in Streptococcus pneumoniae. J Bacteriol, 188(16):‍5797-5805. https://doi.org/10.1128/jb.00336-06https://doi.org/10.1128/jb.00336-06

Lai R, Jeyanathan M, Shaler CR, et al., 2014. Restoration of innate immune activation accelerates Th1-cell priming and protection following pulmonary mycobacterial infection. Eur J Immunol, 44(5):1375-1386. https://doi.org/10.1002/eji.201344300https://doi.org/10.1002/eji.201344300

Lamm DL, Thor DE, Harris SC, et al., 1980. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol, 124(1):38-42. https://doi.org/10.1016/S0022-5347(17)55282-9https://doi.org/10.1016/S0022-5347(17)55282-9

Lamm DL, van der Meijden APM, Morales A, et al., 1992. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol, 147(3):596-600. https://doi.org/10.1016/s0022-5347(17)37316-0https://doi.org/10.1016/s0022-5347(17)37316-0

Larsen ES, Joensen UN, Poulsen AM, et al., 2020. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections. Apmis, 128(2):92-103. https://doi.org/10.1111/apm.13011https://doi.org/10.1111/apm.13011

Leakakos T, Ji C, Lawson G, et al., 2003. Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Cancer Chemother Pharmacol, 51(6):445-450. https://doi.org/10.1007/s00280-003-0597-9https://doi.org/10.1007/s00280-003-0597-9

Liu L, Shen TT, Liu HF, et al., 2021. Toxicity effects of anthracycline-converted herceptin and azo-functionalized Fe3O4 nanoparticles on the heart of patients with breast cancer based on echocardiography. J Nanosci Nanotechnol, 21(2):878-885. https://doi.org/10.1166/jnn.2021.18658https://doi.org/10.1166/jnn.2021.18658

Luo Y, Chen XH, O'Donnell MA, 2003. Role of Th1 and Th2 cytokines in BCG-induced IFN-‍γ production: cytokine promotion and simulation of BCG effect. Cytokine, 21(1):17-26. https://doi.org/10.1016/s1043-4666(02)00490-8https://doi.org/10.1016/s1043-4666(02)00490-8

Luo Y, Yamada H, Chen X, et al., 2004. Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin Exp Immunol, 137(1):24-34. https://doi.org/10.1111/j.1365-2249.2004.02522.xhttps://doi.org/10.1111/j.1365-2249.2004.02522.x

Ma Z, Damania B, 2016. The cGAS-STING defense pathway and its counteraction by viruses. Cell Host Microbe, 19(2):150-158. https://doi.org/10.1016/j.chom.2016.01.010https://doi.org/10.1016/j.chom.2016.01.010

Masuda H, Nakamura T, Noma Y, et al., 2018. Application of BCG-CWS as a systemic adjuvant by using nanoparticulation technology. Mol Pharm, 15(12):5762-5771. https://doi.org/10.1021/acs.molpharmaceut.8b00919https://doi.org/10.1021/acs.molpharmaceut.8b00919

Matsumoto M, Seya T, Kikkawa S, et al., 2001. Interferon gamma-producing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCG cell wall skeleton. Int Immunopharmacol, 1(8):1559-1569. https://doi.org/10.1016/s1567-5769(01)00071-6https://doi.org/10.1016/s1567-5769(01)00071-6

McBride SM, Sonenshein AL, 2011. The dlt operon confers resistance to cationic antimicrobial peptides in Clostridium difficile. Microbiology (Reading), 157(5):1457-1465. https://doi.org/10.1099/mic.0.045997-0https://doi.org/10.1099/mic.0.045997-0

Medrano RFV, Hunger A, Mendonça SA, et al., 2017. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget, 8(41):71249-71284. https://doi.org/10.18632/oncotarget.19531https://doi.org/10.18632/oncotarget.19531

Miyazaki J, Kawai K, Kojima T, et al., 2011a. The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guéin can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands. BJU Int, 108(9):1520-1526. https://doi.org/10.1111/j.1464-410X.2010.10056.xhttps://doi.org/10.1111/j.1464-410X.2010.10056.x

Miyazaki J, Nishiyama H, Yano I, et al., 2011b. The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma. Anticancer Res, 31(6):‍2065-2071.

Morales A, 1978. Adjuvant immunotherapy in superficial bladder cancer. Natl Cancer Inst Monogr, 49:315-319.

Nakamura T, Fukiage M, Higuchi M, et al., 2014. Nanoparticulation of BCG-CWS for application to bladder cancer therapy. J Control Release, 176:44-53. https://doi.org/10.1016/j.jconrel.2013.12.027https://doi.org/10.1016/j.jconrel.2013.12.027

Nave O, Hareli S, Elbaz M, et al., 2019. BCG and IL-2 model for bladder cancer treatment with fast and slow dynamics based on SPVF method‍—‍stability analysis. Math Biosci Eng, 16(5):5346-5379. https://doi.org/10.3934/mbe.2019267https://doi.org/10.3934/mbe.2019267

Nieuwenhuizen NE, Kulkarni PS, Shaligram U, et al., 2017. The recombinant Bacille Calmette-Guérin vaccine VPM1002: ready for clinical efficacy testing. Front Immunol, 8:1147. https://doi.org/10.3389/fimmu.2017.01147https://doi.org/10.3389/fimmu.2017.01147

Niranjan R, Koushik C, Saravanan S, et al., 2013. A novel injectable temperature-sensitive zinc doped chitosan/β‍-glycerophosphate hydrogel for bone tissue engineering. Int J Biol Macromol, 54:24-29. https://doi.org/10.1016/j.ijbiomac.2012.11.026https://doi.org/10.1016/j.ijbiomac.2012.11.026

Ochiai T, Sato H, Hayashi R, et al., 1983. Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. 3- to 6-year follow up of a randomized clinical trial. Cancer Immunol Immunother, 14(3):167-171. https://doi.org/10.1007/bf00205355https://doi.org/10.1007/bf00205355

Park J, Fong PM, Lu J, et al., 2009. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine, 5(4):410-418. https://doi.org/10.1016/j.nano.2009.02.002https://doi.org/10.1016/j.nano.2009.02.002

Patard JJ, Rodriguez A, Leray E, et al., 2002. Intravesical bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol, 41(6):635-642. https://doi.org/10.1016/s0302-2838(02)00173-2https://doi.org/10.1016/s0302-2838(02)00173-2

Perera PY, Lichy JH, Waldmann TA, et al., 2012. The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. Microbes Infect, 14(3):247-261. https://doi.org/10.1016/j.micinf.2011.10.006https://doi.org/10.1016/j.micinf.2011.10.006

Pérez-Jacoiste Asín MA, Fernández-Ruiz M, López-Medrano F, et al., 2014. Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore), 93(17):‍236-254. https://doi.org/10.1097/md.0000000000000119https://doi.org/10.1097/md.0000000000000119

Redelman-Sidi G, Glickman MS, Bochner BH, 2014. The mechanism of action of BCG therapy for bladder cancer‍—a current perspective. Nat Rev Urol, 11(3):153-162. https://doi.org/10.1038/nrurol.2014.15https://doi.org/10.1038/nrurol.2014.15

Rentsch CA, Bosshard P, Mayor G, et al., 2020. Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy. Oncoimmunology, 9(1):1748981. https://doi.org/10.1080/2162402X.2020.1748981https://doi.org/10.1080/2162402X.2020.1748981

Shi WP, Ji YW, Zhang XG, et al., 2011. Characterization of pH- and thermosensitive hydrogel as a vehicle for controlled protein delivery. J Pharm Sci, 100(3):886-895. https://doi.org/10.1002/jps.22328https://doi.org/10.1002/jps.22328

Siegel RL, Miller KD, Fuchs HE, et al., 2021. Cancer statistics, 2021. CA Cancer J Clin, 71(1):7-33. https://doi.org/10.3322/caac.21654https://doi.org/10.3322/caac.21654

Singh AK, Srikrishna G, Bivalacqua TJ, et al., 2021. Recombinant BCGs for tuberculosis and bladder cancer. Vaccine, 39(50):7321-7331. https://doi.org/10.1016/j.vaccine.2021.09.040https://doi.org/10.1016/j.vaccine.2021.09.040

Szoka F, 2008. The art of assembly. Science, 319(5863):‍578-579. https://doi.org/10.1126/science.1154253https://doi.org/10.1126/science.1154253

Takeuchi A, Eto M, Tatsugami K, et al., 2016. Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer. Int Immunopharmacol, 35:327-331. https://doi.org/10.1016/j.intimp.2016.03.007https://doi.org/10.1016/j.intimp.2016.03.007

Tham SM, Mahendran R, Chiong E, et al., 2020. Gmcsf and Ifnα gene therapy improves the response to BCG immunotherapy in a murine model of bladder cancer. Future Oncol, 16(17):1179-1188. https://doi.org/10.2217/fon-2020-0137https://doi.org/10.2217/fon-2020-0137

Tinhofer I, Marschitz I, Henn T, et al., 2000. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood, 95(2):610-618. https://doi.org/10.1182/blood.V95.2.610https://doi.org/10.1182/blood.V95.2.610

Tyagi P, Li ZH, Chancellor M, et al., 2004. Sustained intravesical drug delivery using thermosensitive hydrogel. Pharm Res, 21(5):832-837. https://doi.org/10.1023/b:pham.0000026436.62869.9chttps://doi.org/10.1023/b:pham.0000026436.62869.9c

Verri WA, Cunha TM, Ferreira SH, et al., 2007. IL-15 mediates antigen-induced neutrophil migration by triggering IL-18 production. Eur J Immunol, 37(12):3373-3380. https://doi.org/10.1002/eji.200737488https://doi.org/10.1002/eji.200737488

Waldmann TA, 2015. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol Res, 3(3):219-227. https://doi.org/10.1158/2326-6066.Cir-15-0009https://doi.org/10.1158/2326-6066.Cir-15-0009

Waldmann TA, Lugli E, Roederer M, et al., 2011. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood, 117(18):‍4787-4795. https://doi.org/10.1182/blood-2010-10-311456https://doi.org/10.1182/blood-2010-10-311456

Wang WX, Zhang P, Shan WG, et al., 2013. A novel chitosan-based thermosensitive hydrogel containing doxorubicin liposomes for topical cancer therapy. J Biomater Sci Polym Ed, 24(14):1649-1659. https://doi.org/10.1080/09205063.2013.789357https://doi.org/10.1080/09205063.2013.789357

Wang X, Li J, Wang YQ, et al., 2009. HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano, 3(10):‍3165-3174. https://doi.org/10.1021/nn900649vhttps://doi.org/10.1021/nn900649v

World Health Organization, 2018. BCG vaccine: WHO position paper, February 2018 – Recommendations. Vaccine, 36(24):3408-3410. https://doi.org/10.1016/j.vaccine.2018.03.009https://doi.org/10.1016/j.vaccine.2018.03.009

Wu JJ, Zhao L, Hu HG, et al., 2020. Agonists and inhibitors of the STING pathway: potential agents for immunotherapy. Med Res Rev, 40(3):1117-1141. https://doi.org/10.1002/med.21649https://doi.org/10.1002/med.21649

Wurpel DJ, Beatson SA, Totsika M, et al., 2013. Chaperone-usher fimbriae of Escherichia coli. PLoS ONE, 8(1):e52835. https://doi.org/10.1371/journal.pone.0052835https://doi.org/10.1371/journal.pone.0052835

Yamada H, Matsumoto S, Matsumoto T, et al., 2000. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. J Urol, 164(2):526-531. https://doi.org/10.1016/S0022-5347(05)67417-4https://doi.org/10.1016/S0022-5347(05)67417-4

Yamamoto S, Tsukamoto T, Terai A, et al., 1997. Genetic evidence supporting the fecal-perineal-urethral hypothesis in cystitis caused by Escherichia coli. J Urol, 157(3):1127-1129. https://doi.org/10.1016/S0022-5347(01)65154-1https://doi.org/10.1016/S0022-5347(01)65154-1

Zaharoff DA, Hoffman BS, Hooper HB, et al., 2009. Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. Cancer Res, 69(15):6192-6199. https://doi.org/10.1158/0008-5472.Can-09-1114https://doi.org/10.1158/0008-5472.Can-09-1114

Zhang D, Sun P, Li P, et al., 2013. A magnetic chitosan hydrogel for sustained and prolonged delivery of Bacillus Calmette-Guérin in the treatment of bladder cancer. Biomaterials, 34(38):10258-10266. https://doi.org/10.1016/j.biomaterials.2013.09.027https://doi.org/10.1016/j.biomaterials.2013.09.027

Zhang L, Gu FX, Chan JM, et al., 2008. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther, 83(5):761-769. https://doi.org/10.1038/sj.clpt.6100400https://doi.org/10.1038/sj.clpt.6100400

Zhang W, Xu L, Park HB, et al., 2020. Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy. Nat Commun, 11:1187. https://doi.org/10.1038/s41467-020-15030-4https://doi.org/10.1038/s41467-020-15030-4

Zhang Y, Huo F, Cao Q, et al., 2022. FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer. J Immunother Cancer, 10(3):e003939. https://doi.org/10.1136/jitc-2021-003939https://doi.org/10.1136/jitc-2021-003939

浏览量

Downloads

CSCD

工具集

关联资源

Integrative analysis of prognostic long non-coding RNAs with copy number variation in bladder cancer

Exosomes in bladder cancer: novel biomarkers and targets

Lymphatic vasculature in tumor metastasis and immunobiology

Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma